Navigation Links
Surgex(TM) Becomes the First and Only BSCG (Banned Substance Control Group) Certified Product Which is Clinically Proven Effective in Sports Recovery and Performance
Date:1/29/2008

fessionalism in the sports nutrition sector.

The final set of results from Millennium's sponsored Division 1 Football trial at Rutgers University have shown that Surgex(TM) had a significant effect on recovery markers including testosterone:cortisol ratios compared to a market leading sports beverage on the market. "Along with our previous statistically significant improvements in body composition and strength parameters, the recovery marker data continues to validate Surgex(TM) as an important nutritional adjunct for the athlete" states Mr. Germano. "As we have seen in the medical market, Surgex is now able to offer the athlete a product that will assist in recovery in efforts to improve performance. In addition, our participation in the BSCG program continues to set us apart from the competition."

The continued usage and acceptability of Surgex(TM) by Professional, Olympic, and Collegiate athletes is providing the valuable market information which will allow Millennium to develop the best strategy to commercialize Surgex(TM), expected in Q3 of 2008.

About Surgex(TM):

Surgex(TM) (http://www.surgexsports.com) was created from Millennium's extensive experience providing advanced nutritional formulas to some of the most prestigious medical institutions throughout the United States The proprietary Surgex(TM) formula intends to meet the growing demand of elite level Professional, Olympic and amateur athletes and their coaches looking for nutritional support in a marketplace dominated by products with no clinical proof of benefit, unsubstantiated claims, excess protein, stimulants, and banned substances.

In double blind placebo controlled trials at the Rutgers University Human Performance Lab Surgex(TM) significantly outperformed leading competitive products by assisting in reducing the damaging effects of exercise by improving peak power outputs, lowering oxidative stress/inflamma
'/>"/>

SOURCE Millennium Biotechnologies Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia
2. Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency
3. Cleveland Clinic to Lead First Head-to-Head Comparison of the Two Most Potent Statins
4. First Patient Enrolled in Cogentus Pharmaceuticals Pivotal Phase 3 Trial of Novel Combination Medicine
5. VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation
6. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
7. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
8. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers
9. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
10. Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting
11. YMed, Inc. Successfully Completes First Clinical Cases With Innovative VascuTraK(TM) II PTA Dilatation Catheter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... Bend Research Inc. announced,today that its clients may now ... in technologies developed by the firm to enhance the ... Bend Research clients may now reference a Type ... with the FDA, Bend Research officials said. , ... and know it will assist our,clients in accelerating the ...
(Date:12/14/2009)... Research Group, Inc. released ChartTrends®: Biologics in ... insight into the management of RA patients. ... self-reported treatment approaches (as reported by 208 Rheumatologists) ... RA patients who are currently being treated with ... audit, patients had to currently be treated with ...
(Date:12/14/2009)... 14 Seven leading cancer ... US Oncology Research participated in ... the 2009 San Antonio Breast ... at the Henry B. Gonzalez ... Texas . Fifteen others presented ...
Breaking Medicine Technology:Bend Research Clients May Now Reference Key Safety Document for Important Solubility Excipient 2New Market Research Report from BioTrends Provides Insight on How Rheumatologists are Utilizing Biologic Agents in the Treatment of Rheumatoid Arthritis 2New Market Research Report from BioTrends Provides Insight on How Rheumatologists are Utilizing Biologic Agents in the Treatment of Rheumatoid Arthritis 3US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 2US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 3US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 4US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 5US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 6US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 7US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 8US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 9Repeat negative CT scan for lung cancer does not encourage ex smokers to resume the habit 10966 1Repeat negative CT scan for lung cancer does not encourage ex smokers to resume the habit 10966 2Reportlinker Adds Point of Care Diagnostics 62494 1Reportlinker Adds Point of Care Diagnostics 62494 2Reportlinker Adds Point of Care Diagnostics 62494 3Reportlinker Adds Point of Care Diagnostics 62494 4Reportlinker Adds Point of Care Diagnostics 62494 5Reportlinker Adds Point of Care Diagnostics 62494 6Reportlinker Adds Point of Care Diagnostics 62494 7Reportlinker Adds Point of Care Diagnostics 62494 8Reportlinker Adds Point of Care Diagnostics 62494 9Reportlinker Adds Point of Care Diagnostics 62494 10Reportlinker Adds Point of Care Diagnostics 62494 11Reportlinker Adds Point of Care Diagnostics 62494 12Natural Products Association Issues Statement on New Supplement Safety Campaign 62490 1Natural Products Association Issues Statement on New Supplement Safety Campaign 62490 2
... KENILWORTH, N.J., May 30 Schering-Plough,Corporation (NYSE: ... poster,discussions, and oral presentations from about 60 clinical ... presented at the upcoming 44th,Annual Meeting of the ... 30 - June 3. Data will be presented ...
... safety and tolerability, as well as ... -, ROCKVILLE, Md., May 30 Human Genome ... has initiated dosing in a Phase,1 clinical trial to ... HGS1029, as monotherapy in patients with advanced solid tumors., ...
Other Medicine Technology:About 60 Clinical Studies Regarding Schering-Plough's Oncology Compounds Will be Presented at ASCO 2Human Genome Sciences Initiates First Clinical Trial of Lead IAP Inhibitor HGS1029 in Advanced Solid Tumors 2Human Genome Sciences Initiates First Clinical Trial of Lead IAP Inhibitor HGS1029 in Advanced Solid Tumors 3Human Genome Sciences Initiates First Clinical Trial of Lead IAP Inhibitor HGS1029 in Advanced Solid Tumors 4
(Date:12/15/2009)... Dec. 15 Today, Coastal Healthcare ... Clara County for the first time since ... Coastal Healthcare Administrators will be assuming responsibilities ... Physicians Foundation for Medical Care. ,, ... Coastal maintains close working relationships with all ...
(Date:12/15/2009)... often treated with hormones, but when the tumours start ... reveals a thesis from the Sahlgrenska Academy, at the ... for new treatments for hormone-resistant prostate cancer. , Late ... cancer has spread, most patients are given hormone therapy. ... and the tumour shrinks. , "The problem is that ...
(Date:12/15/2009)... new study published by The University of Western Ontario ... and unpaid work report higher average measures of happiness ... , The ,shared roles, category, where each partner,s unpaid ... unpaid work, is a growing category that now represents ... more likely to be in a shared roles model ...
(Date:12/15/2009)... Although seen as a potential heart disease therapy, raising ... a transfer protein may not be effective, a new ... Nutrition Research Center on Aging (USDA HNRCA) at Tufts ... an association between low plasma cholesterol ester transfer protein ... the Framingham Heart Study population. , CETP is a ...
(Date:12/15/2009)... about-face, the secretive Central Intelligence Agency has requested documents from ... them from the CIA itself under the Freedom of Information ... ... 15, 2009 -- In a bizarre about-face, the secretive Central ... though the writer had earlier obtained them from the CIA ...
Breaking Medicine News(10 mins):Health News:Coastal Healthcare Administrators Expands Provider Network to Santa Clara County 2Health News:More blood vessels in hormone-resistant prostate tumors 2Health News:Low cholesterol transfer protein activity associated with heart disease risk 2Health News:CIA Requests its Own Documents from Author 2Health News:CIA Requests its Own Documents from Author 3
... building in the,surgical community and among industry sponsors ... February 18-23, 2008 in,Steamboat Springs, Colorado. The MISS ... in addition to its flagship sessions on,morbid obesity., ... MISS 2008 will expound,on the integrated, multidisciplinary team ...
... Jan. 25 MiddleBrook,Pharmaceuticals, Inc. (Nasdaq: MBRK ... novel anti-infective products, today,announced that it has entered ... private placement of 8,750,000 shares of,its common stock ... warrants to purchase 3,500,000 shares of common stock ...
... Los Angeles, London, New Delhi, and Singapore (25 January, ... Analytic Therapy (CAT) is published in a third edition ... practical psychotherapy. , Building on the success and popularity ... (published by SAGE) illustrates in ordinary language how learned ...
... Center to Open Melrose, Massachusetts Location in ... ... New England announces the opening of a new office in Melrose, Mass. ... The,Melrose office, located at 830 Main Street, Suite 207, will begin,scheduling patients ...
... WASHINGTON, Jan. 24 U.S. Department of,Health ... recognized the first,set of interoperability standards developed ... http://www.hitsp.org ). The HITSP advanced three,of ... advancement of,interoperable health records and a Nationwide ...
... In observance of,National Children,s Dental Health Month ... sponsoring its annual poster,contest. All Pennsylvania third-grade students ... grand prize winner will receive a $1,000 education ... bookmarks to be distributed to all of,Pennsylvania,s public ...
Other Medicine News:Health News:Thought Leaders in Morbid Obesity Treatment Convene at Upcoming Surgical Conference 2Health News:MiddleBrook Pharmaceuticals to Raise $21 Million Through Private Placement of Common Equity 2Health News:MiddleBrook Pharmaceuticals to Raise $21 Million Through Private Placement of Common Equity 3Health News:MiddleBrook Pharmaceuticals to Raise $21 Million Through Private Placement of Common Equity 4Health News:Change for the better back with third edition 2Health News:Leading IVF Practice to Open 11th New England Location 2Health News:HHS Secretary Recognizes Products of HITSP Standards Work 2Health News:HHS Secretary Recognizes Products of HITSP Standards Work 3Health News:HHS Secretary Recognizes Products of HITSP Standards Work 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: